Prostate Cell News Volume 4.49 | Dec 20 2013

Polyphenon E^®, a Standardized Green Tea Extract, Induces Endoplasmic Reticulum Stress, Leading to Death of Immortalized PNT1a Cells by Anoikis and Tumorigenic PC3 by Necroptosis
Increasing doses of Polyphenon E^® were given to PNT1a and PC3 prostate epithelial cells mimicking initial and advanced stages of prostate cancer, respectively. Cell death occurred in both cell lines, with PNT1a being more sensitive than PC3 to Polyphenon E^®. [Carcinogenesis] Abstract

Diet-Induced Macrophage Inhibitory Cytokine 1 Promotes Prostate Cancer Progression
The authors investigated the mechanism underlying the association of dietary fat, including palmitic acid, with prostate cancer progression. [Endocr Relat Cancer] Abstract

Epigenetic regulation of MDR1 Gene through Post-Translational Histone Modifications in Prostate Cancer
Multidrug resistance 1 (MDR1) promoter methylation and P-glycoprotein expression were assessed in 121 prostate carcinomas, 39 high-grade prostatic intraepithelial neoplasia , 28 benign prostatic hyperplasia and 10 morphologically normal prostate tissue samples, using quantitative methylation specific polymerase chain reaction and immunohistochemistry, respectively. [BMC Genomics] Abstract | Full Article

Exosomes Secreted Under Hypoxia Enhance Invasiveness and Stemness of Prostate Cancer Cells by Targeting Adherens Junction Molecules
The authors analyzed the role of exosomes from hypoxic prostate cancer (PCA) cells in enhancing the invasiveness and stemness of naïve PCA cells, as well as in promoting cancer-associated fibroblast phenotype in prostate stromal cells. [Mol Carcinog] Abstract

Dual PI3K/mTOR Inhibitor NVP-BEZ235 Sensitizes Docetaxel in Castration Resistant Prostate Cancer
Researchers explored the efficacy of NVP-BEZ235, a dual phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR) complex 1/2 inhibitor, for docetaxel resistant castration resistant prostate cancer. [J Urology] Abstract

Skp2 Regulates Androgen Receptor through Ubiquitin-Mediated Degradation Independent of Akt/mTOR Pathways in Prostate Cancer
Researchers discovered that S-phase kinase-associated protein 2 (Skp2) is an E3 ubiquitin ligase for androgen receptor (AR) degradation, and revealed a possible mechanism on AR regulation in advanced prostate cancer. [Prostate] Abstract

CLINICAL RESEARCH

Targeted Androgen Pathway Suppression in Localized Prostate Cancer: A Pilot Study
Investigators evaluated combinations of CYP17A and 5-α-reductase inhibitors for reducing prostate androgen levels, androgen receptor signaling, and prostate cancer volumes. [J Clin Oncol] Abstract

Association Between Neuraxial Analgesia, Cancer Progression, and Mortality After Radical Prostatectomy: A Large, Retrospective Matched Cohort Study
Researchers tested the hypothesis that supplementing general anaesthesia with neuraxial analgesia improves long-term oncological outcomes in patients having radical prostatectomy for adenocarcinoma. [Brit J Anaesth] Abstract | Press Release

Decreased Expression of MYL9 in Stroma Predicts Malignant Progression and Poor Biochemical Recurrence-Free Survival in Prostate Cancer
Researchers investigated the associations of MYL9 downregulation with tumor progression and prognosis in patients with prostate cancer. [Med Oncol] Abstract

Association of MicroRNA-126 Expression with Clinicopathological Features and the Risk of Biochemical Recurrence in Prostate Cancer Patients Undergoing Radical Prostatectomy
The authors investigated microRNA-126 expression in prostate cancer (PCa) and its prognostic value for PCa patients undergoing radical prostatectomy. [Diagn Pathol] Abstract | Full Article

Visit our reviews page to see a complete list of reviews in the prostate cell research field.

Bayer HealthCare Announces Collaboration with the University of Texas MD Anderson Cancer Center
Bayer HealthCare announced that the company has signed a master agreement for the performance of clinical trials with the Houston-based University of Texas MD Anderson Cancer Center. The agreement aims to bolster ongoing and future collaborative clinical programs in oncology and bring new cancer treatments to patients. [Bayer HealthCare] Press Release

From our sponsor:
Interested in assays for human mammary stem and progenitor cells? Request your free wallchart.

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the prostate cell community.

NEW PhD Studentship – Spectroscopic Biopsy of the Prostate (Academic Medical Center)

Postdoctoral Position – Stem Cells and Bioengineering (Queensland University of Technology/Translational Research Institute)

Postdoctoral Fellow – Molecular Mechanisms of Prostate Cancer (Northwestern University- Feinberg School of Medicine)

Clinical MD – Clinical Development Program for Oncology and Autoimmune Diseases (Immunomedics, Inc.)

Chief Medical Officer – Novel Therapeutics in Oncology and Autoimmune Disease (Immunomedics, Inc.)

Postdoctoral Position – Chemistry and Prostate Cancer Imaging (University of California San Francisco)

Postdoctoral Fellow – Mechanisms Promoting Castrate Resistant Prostate Cancer (Mount Sinai School of Medicine)

Postdoctoral Fellow – Development and Progression of Prostate Cancer (University of Maryland Baltimore, School of Medicine)

Scientist – Particle Chemistry (STEMCELL Technologies Inc.)

Research Technologist – Human Pluripotent Stem Cell Products (STEMCELL Technologies Inc.)

Research Associate/Scientist – Antibodies Group (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.